

# Fiscal Year (FY24) Prescription Drug Affordability Fund Fee Assessment Updates

---

January 23, 2023

Andrew York, Executive Director

Maryland Prescription Drug Affordability Board

# Agenda

---

- 🇺🇸 Summary of FY22 and FY23 Fee Assessment Updates
- 🇺🇸 Fee Assessment: Updates for FY 24



# Summary of FY22 and FY23 Fee Assessment Policies

---

- ✚ \$1000 flat annual fee assessment on:
  - Manufacturers that sell or offer for sale prescription drug products to persons in the State;
  - Pharmacy benefits managers, as defined in § 15–1601 of the Insurance Article;
  - Carriers, as defined in § 19–132 of this article; and,
  - Wholesale distributors, as defined in § 12–6C–01 of the Health Occupations Article, that sell or offer for sale prescription drug products to persons in the State
- ✚ Waiver process to waive the assessment for entities if the fee assessment exceeds 1% of revenue earned in Maryland during preceding fiscal year
- ✚ Exemption process if entity is not subject to the assessment because it is not a qualifying entity under COMAR 14.01.01 and Health General § 21-2C-11(b)(1)



# Results of FY22 Fee Assessment

---




## 1505 Invoices Sent

- 881 entities have paid, with \$881,000 in FY22 revenue
  - Approved Waivers and Exemptions: Approximately 217
    - Waivers- Approximately 103 Approved
    - Exemptions- Approximately 114 Denied
  - Denied Waivers and Exemptions: 303
- Sending approximately 400 Delinquent Notices
  - Outstanding invoices will be sent to collections



# Potential Updates for FY24 Fee Assessment

---

-  Create a process to remove entities from the Fee Assessment master list
-  Eliminate the Waiver process
-  Nominal increase to the Fee Assessment Amount



**MARYLAND**

Prescription Drug Affordability Board

---

**[support.pdab@maryland.gov](mailto:support.pdab@maryland.gov)**

[pdab.maryland.gov](http://pdab.maryland.gov)